ProShares UltraShort NASDAQ Biotechnology
14 hedge funds and large institutions have $30.8M invested in ProShares UltraShort NASDAQ Biotechnology in 2016 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 7 closing their positions.
474% more call options, than puts
Call options by funds: $55.1M | Put options by funds: $9.6M
81% more capital invested
Capital invested by funds: $17M → $30.8M (+$13.8M)
7% less funds holding
Funds holding: 15 → 14 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAP
Ardsley Advisory Partners
Stamford,
Connecticut
|
+$15.9M |
| 2 |
VF
Virtu Financial
New York
|
+$4.48M |
| 3 |
FAM
Fred Alger Management
New York
|
+$1.43M |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$1.18M |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
+$999K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
-$8.38M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.31M |
| 3 |
CAM
Chesapeake Asset Management
New York
|
-$912K |
| 4 |
EM
Emancipation Management
New York
|
-$643K |
| 5 |
PCM
Prelude Capital Management
New York
|
-$287K |
BIS Hedge Fund Activity: Q1 2016 in Review
14 of the 3,754 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2016, worth a combined $30.8M — up 81% from $17M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of BIS and 6 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.
The largest buyer was Ardsley Advisory Partners, adding an estimated $15.9M. The largest seller was Highland Capital Management (Texas), exiting entirely with an estimated $8.38M sold.
- 14 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2016, down from 15 in Q4 2015.
- Funds reported $30.8M of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2016, up 81% quarter-over-quarter.
- 6 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2016 and 7 closed out, a net change of -1 holder.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2016 was Ardsley Advisory Partners, an estimated $15.9M added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2016 was Highland Capital Management (Texas), an estimated $8.38M sold.
Based on aggregated 13F filings for Q1 2016.